Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Grant Zeng, who discusses Sangamo Bioscience (Nasdaq: SGMO), Lexicon Pharmaceuticals (Nasdaq: LXRX) and Critical Therapeutics (Nasdaq: CRTX).
A synopsis of today’s Analyst Interview is presented below. The full article can be read at http://at.zacks.com/?id=2678.
What are some of your top Buy-recommended stocks at this time?
At this time, I have quite a few companies with Buy recommendations. The first one is Sangamo Bioscience (Nasdaq: SGMO). I like this company because it has a platform called transcription factor technology, which is unique to the industry and the company is the market leader in this field. Also, the company has a decent pipeline, with many candidates in the development stage.
Another company I like is called Lexicon Pharmaceuticals (Nasdaq: LXRX), which is similar to Sangamo Bioscience. This company also has a platform technology called “gene knockout.” The company is a market leader in this area. And also the company has a decent pipeline, and has recently signed a few deals.
Another one is called Critical Therapeutics (Nasdaq: CRTX). This company actually has two products in the market, called Zyflo and Zyflo CR. These two products are indicated for asthma. So this tiny biotech company we feel can compete in the huge asthma market, although this market is also very competitive. I recently initiated coverage of this stock with a Buy recommendation.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros by going to http://at.zacks.com/?id=2648.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
(a)The Zacks Performance Rank performance is the total return of equal weighted simulated portfolios consisting of those stocks with the indicated Zacks Rank net of fees. Results reflect the reinvestment of dividends and other earnings. Simulated results do not represent actual trading and may not reflect the impact that economic and market factors might have had on decision-making if an adviser were actually managing a client's money.
(b)The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.